Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%
Lithium
44.18
0.89%
Gold
2,638.60
0.7%
Copper
4.14
0.01%
Oil
67.20
(1.81%)
Bitcoin
99,729.91
(0.14%)
FTSE 100
8,308.60
(0.49%)
Nikkei 225
39,091.17
(0.71%)
Dow Jones
44,642.52
(0.41%)
Iron Ore
102.55
(1.19%)
USD/AUD
0.64
-0%
Hang Seng
19,865.85
1.3%

Argenica Therapeutics Ltd

AGN

ASX

Argenica Therapeutics Limited (AGN) is actively engaged in pioneering research and development focused on neuroprotective therapeutic drugs. Their primary objective is to innovate novel treatments aimed at mitigating brain damage following stroke. By advancing these neuroprotective therapies, Argenica Therapeutics seeks to address critical needs in stroke care, potentially improving outcomes and quality of life for patients affected by this debilitating condition.

Latest Posts

Line Chart with Gradient
Price
$0.655
-0.005 (-0.76%)
At Close 06/12 (AEST)
Related Companies
OPTHEA LIMITED
$OPT
CAMBIUM BIO LIMITED
$CMB
CLEO DIAGNOSTICS LTD
$COV
CSL LIMITED
$CSL
STARPHARMA HOLDINGS LIMITED
$SPL

Leave a Comment on AGN


Comments for AGN

    Latest Posts

    argenica-therapeutics-asx-agn-receives-cash-rebate-for-rd-activities-agn
    Health Care $AGN
    Argenica Therapeutics (ASX: $AGN) receives cash rebate for R&D activitiesArgenica secures $2.7M from the Australian R&D Tax Incentive Program for FY24 clinical developments
    November 21, 2024
    argenica-therapeutics-asx-agn-progresses-phase-2-clinical-trial-of-arg-007-agn
    Health Care $AGN
    Argenica Therapeutics (ASX: $AGN) progresses phase 2 clinical trial of ARG-007Positive safety outcomes reported; trial for neuroprotective peptide continues with no serious adverse events.
    November 1, 2024
    argenica-therapeutics-asx-agn-completes-key-safety-studies-confirming-competitive-position-of-arg-007-agn
    Health Care $AGN

    Argenica Therapeutics (ASX: $AGN) completes key safety studies confirming competitive position of arg-007

    IND enabling studies confirm ARG-007's unique mechanism of action and pharmacological benefits

    September 25, 2024
    argenica-therapeutics-asx-agn-progresses-phase-2-stroke-trial-agn
    Health Care $AGN

    Argenica Therapeutics (ASX: $AGN) progresses phase 2 stroke trial

    DSMB recommends continuation of ARG-007 trial with no modifications

    September 6, 2024
    argenica-therapeutics-asx-agn-demonstrates-efficacy-of-arg-007-in-reducing-traumatic-brain-injury-effects-agn
    Health Care $AGN

    Argenica Therapeutics (ASX: $AGN) demonstrates efficacy of ARG-007 in reducing traumatic brain injury effects

    Study shows significant reduction in brain cell damage and inflammation markers in ferret model

    May 15, 2024
    argenica-therapeutics-asx-agn-commences-phase-2-stroke-trial-agn
    Health Care $AGN

    Argenica Therapeutics (ASX: $AGN) commences phase 2 stroke trial

    Successfully dosed first patients in ARG-007 trial, granted Rare Pediatric Disease Designation

    April 24, 2024
    argenica-therapeutics-asx-agn-completes-12-0m-placement-agn
    Health Care $AGN

    Argenica Therapeutics (ASX: $AGN) completes $12.0m placement

    Successfully raises funds to progress Phase 2 trial of ARG-007 in ischaemic stroke patients

    April 12, 2024
    argenica-therapeutics-asx-agn-achieves-patient-dosing-milestone-in-stroke-trial-agn
    Health Care $AGN

    Argenica Therapeutics (ASX: $AGN) achieves patient dosing milestone in stroke trial

    First cohort of acute ischaemic stroke patients dosed in Phase 2 clinical trial of ARG-007

    April 10, 2024
    argenica-therapeutics-asx-agn-requests-trading-halt-for-capital-raising-announcement-agn
    Health Care $AGN

    Argenica Therapeutics (ASX: $AGN) requests trading halt for capital raising announcement

    Company requests halt ahead of capital raising news

    April 10, 2024
    argenica-therapeutics-asx-agn-doses-first-patient-in-phase-2-stroke-trial-of-arg-007-agn
    Health Care $AGN

    Argenica Therapeutics (ASX: $AGN) doses first patient in phase 2 stroke trial of ARG-007

    Phase 2 trial commences with successful dosing of acute ischaemic stroke patient

    March 28, 2024
    argenica-therapeutics-asx-agn-progresses-phase-2-stroke-clinical-trial-agn
    Health Care $AGN

    Argenica Therapeutics (ASX: $AGN) progresses phase 2 stroke clinical trial

    Manufacturing of drug substance completed, hospital trial sites set up, and independent DSMB established

    January 14, 2024
    argenica-therapeutics-asxagn-progresses-phase-2-stroke-clinical-trial-agn
    Health Care $AGN

    Argenica Therapeutics (ASX:$AGN) progresses phase 2 stroke clinical trial

    Manufacturing of drug substance completed, hospital trial sites set up, and independent DSMB established

    December 14, 2023

    AGN

    $AGN

    Argenica Therapeutics (ASX: $AGN) receives cash rebate for R&D activities

    Argenica secures $2.7M from the Australian R&D Tax Incentive Program for FY24 clinical developments

    AGN

    $AGN

    Argenica Therapeutics (ASX: $AGN) progresses phase 2 clinical trial of ARG-007

    Positive safety outcomes reported; trial for neuroprotective peptide continues with no serious adverse events.

    AGN

    $AGN

    Argenica Therapeutics (ASX: $AGN) completes key safety studies confirming competitive position of arg-007

    IND enabling studies confirm ARG-007's unique mechanism of action and pharmacological benefits

    AGN

    $AGN

    Argenica Therapeutics (ASX: $AGN) progresses phase 2 stroke trial

    DSMB recommends continuation of ARG-007 trial with no modifications

    AGN

    $AGN

    Argenica Therapeutics (ASX: $AGN) demonstrates efficacy of ARG-007 in reducing traumatic brain injury effects

    Study shows significant reduction in brain cell damage and inflammation markers in ferret model

    AGN

    $AGN

    Argenica Therapeutics (ASX: $AGN) commences phase 2 stroke trial

    Successfully dosed first patients in ARG-007 trial, granted Rare Pediatric Disease Designation

    AGN

    $AGN

    Argenica Therapeutics (ASX: $AGN) completes $12.0m placement

    Successfully raises funds to progress Phase 2 trial of ARG-007 in ischaemic stroke patients

    AGN

    $AGN

    Argenica Therapeutics (ASX: $AGN) achieves patient dosing milestone in stroke trial

    First cohort of acute ischaemic stroke patients dosed in Phase 2 clinical trial of ARG-007

    AGN

    $AGN

    Argenica Therapeutics (ASX: $AGN) requests trading halt for capital raising announcement

    Company requests halt ahead of capital raising news

    AGN

    $AGN

    Argenica Therapeutics (ASX: $AGN) doses first patient in phase 2 stroke trial of ARG-007

    Phase 2 trial commences with successful dosing of acute ischaemic stroke patient

    Load More
    No More Posts
    Related Companies
    EPSILON HEALTHCARE LIMITED
    $EPN
    CSL LIMITED
    $CSL
    TELIX PHARMACEUTICALS LIMITED
    $TLX
    TRAJAN GROUP HOLDINGS LIMITED
    $TRJ
    PYC THERAPEUTICS LIMITED
    $PYC

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions